NICE

NICE Blocks J&J Prostate Cancer Drug Abiraterone

NICE Blocks J&J Prostate Cancer Drug Abiraterone

National Institute for Health and Care Excellence (NICE) has decided to block Johnson & Johnson’s prostate cancer drug. In an official communication, NICE informed that it is not worth giving the medicine to patients who have not received chemotherapy. The Institute of Cancer Research (ICR) health experts had suggested abiraterone acetate for men before they undergo chemotherapy.

Location: 
Laboratories: 

Kadcyla, Novel Breast Cancer Drug Launch in UK

Kadcyla, Novel Breast Cancer Drug Launch in UK

UK welcomes the launch of new drug, Kadcyla, to treat terminal condition breast cancer in women who failed to respond to conventional treatment with Herceptin and chemotherapy.

Laboratories: 
Location: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More